A study presented at the European Association of Percutaneous Cardiovascular Interventions' annual congress showed percutaneous left atrial appendage closure using St. Jude Medical's Amplatzer device in patients with nonvalvular atrial fibrillation had a lower rate of the composite primary efficacy endpoint, consisting of systemic embolism, stroke and cardiovascular or unexplained mortality, than that of oral anticoagulation. The device therapy also led to a lower rate of the composite safety endpoint, composed of major bleeding and major procedural adverse events.
Study shows positive results for St. Jude's Amplatzer device
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.